Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024530 (malaria)
 44,886 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of human African trypanosomiasis (sleeping sickness) is described. A crude extract of a Trypanosoma brucei suspension which was purified from all blood components was used as antigen. In rabbits experimentally infected with T. brucei or T. rhodesiense both homologous (anti-T. brucei) and heterologous (anti-T. rhodesiense) Trypanosoma antibodies could be detected with ELISA using T. brucei as antigen. The sensitivity of ELISA was comparable with that of the immunofluorescence (IF) technique. Sera of patients with sleeping sickness were examined with ELISA and IF. It proved possible to discriminate between groups of individuals with and without trypanosomiasis. Cross reactions were only observed with serum from a patient in which antibodies to Leishmania were detected. No cross reactions were observed in sera from patients with malaria, toxoplasmosis, schistosomiasis, or echinococcosis. ELISA represents a good alternative to IF in the serology of African trypanosomiasis, and may be particularly suitable for mass screening purposes.
 ...
PMID:Application of the enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of human African trypanosomiasis (sleeping sickness). 32 Aug 95

The risk of acquiring a transfusion-induced infection in Zambia was studied for the first time. Blood slide examination of donors, despite the insensitivity of the method, established malaria as the most serious hazard. The species involved was Plasmodium falciparum, the cause of cerebral malaria, and which could be rapidly fatal in a non-immune host visiting an endemic area. Microfilariae of Dipetalonema perstans and Wuchereria bancrofti were also found in donor populations. While no disease may be induced, allergic reactions due to the breakdown products of dead microfilariae may manifest themselves. Several cases of transfusion-induced malaria, a case of relapsing fever and a case of rhodesian trypanosomiasis are reported. Toxoplasmosis and kalatazar, which may also be transfusion-induced, are both known to occur in the country but no cases were observed. It is emphasized that prophylactic measures should be mandatory in areas where no regular, screened, donor panel is available. The awareness and ackowledgement of the risk of transfusion-induced infections may be the best safeguard against the serious consequences in developing countries.
 ...
PMID:Some transfusion-induced parasitic infections in Zambia. 39 89

A review of 1987 patients with uveitis seen over an 11-year period in Bendel State of Nigeria has been undertaken; 56% of cases had a posterior/mid-peripheral uveitis, 15.1% a panuveitis, 21.5% an anterior uveitis. Acute anterior uveitis with classical symptoms was rarely seen. Its comparative rarity is presumably due to the absence of HL-A27 in Africans and altered immunological states from malaria and parasitic infections. Identified aetiological factors in anterior uveitis were leprosy (1 patient), tuberculosis (1 patient), herpes zoster (16 patients), and onchocerciasis (3 patients). The great majority of cases of posterior uveitis were of presumed toxoplasmic origin. Further studies are needed to demonstrate its mode of transmission in a population in which toxoplasmosis is endemic. Forest onchocerciasis is not a major cause of uveitis in southern Nigeria in the same way as savanna onchocerciasis is in northern Nigeria. Syphilis seems to play no part in the causation of uveitis in southern Nigeria. Better diagnostic facilities are required to determine the role of sarcoidosis and other possible causative factors. Uveitis is a major cause of blindness in Nigeria.
 ...
PMID:The problem of uveitis in Bendel State of Nigeria: experience in Benin City. 56 37

The specificity of a circulating antibody observed in American trypanosomiasis and reacting with endocardium, blood vessels, and the interstitium of striated muscle (EVI factor) was evaluated in the indirect fluorescent antibody test with 60 sera from patients with malaria, leishmaniasis, echinococcosis, amebiasis, African trypanosomiasis, toxoplasmosis, and trichinosis, collected from areas where Chagas' disease is not endemic. Two sera, 1 from a patient with Plasmodium falciparum malaria and 1 from a patient with a relapse pretreatment post kala-azar dermal leishmaniasis, were positive for the EVI factor. In the leishmaniasis group, 3 of 8 sera reacted with 0ovine, murine, and human skeletal muscle. In this reaction, which differs from the EVI test, the sarcolemma and the intracellular structures were stained.
 ...
PMID:Investigation of the EVI antibody in parasitic diseases other than American trypanosomiasis. An anti-skeletal muscle antibody in leishmaniasis. 108 66

The risks of morbidity and mortality associated with transfusion are so great that no transfusion should be given until it is decided that it is absolutely necessary and then only with the utmost care. The unfavorable effects of transfusion reviewed are: hemolytic reaction; bacterial contamination; febrile reaction due to leukoagglutinins; urticaria; anaphylaxis; problems associated with the transfusion of excess potassium, ammonia, and acid; transmission of hepatitis, cytomegalic inclusion disease, toxoplasmosis, and malaria; pulmonary insufficiency; air embolism; and circulatory overload.
 ...
PMID:Adverse effects of transfusions. 126 10

A commercial EIA for the detection of antibody to Trypanosoma cruzi was clinically evaluated. The primary use of this test is in the diagnosis and screening of donated blood in Latin America. When compared with sera positive by xenodiagnosis, the assay had a clinical sensitivity of 100%. When tested against matched hemagglutination (HA) and immunofluorescence (IFA) results (i.e., when both tests gave negative results) the EIA had a specificity of 99.03% (305/308). The cross-reactivity of this test was determined using sera from malaria and leishmaniasis patients (obtained from Africa, ensuring that the sera did not contain Chagasic antibodies) and from schistosomiasis, toxoplasmosis, tuberculosis, syphilis, and systemic lupus erythematosus samples. The EIA was 100% specific whereas IFA or commercially available HA kits from Latin America cross-reacted with several of the samples. In this investigation, the EIA appeared to be at least as sensitive and more specific than IFA or HA in the serodiagnosis of Chagas' disease.
 ...
PMID:Clinical evaluation of an EIA for the sensitive and specific detection of serum antibody to Trypanosoma cruzi (Chagas' disease). 153 65

In recent years, introduction of new and more effective agents has improved the overall therapy for parasitic infections. This field, however, is still plagued by numerous problems, including the development of resistance to antimicrobial agents (especially with malaria), unavailability of agents in the United States or lack of approval by the Food and Drug Administration, and major toxicities or lack of experience in pregnant women and children, which limits use in these groups of patients. Widespread resistance of Plasmodium falciparum to chloroquine and other agents has complicated the treatment and prophylaxis of this type of malaria. A combination of quinine and Fansidar is usually effective oral therapy for falciparum malaria; quinidine may be administered if intravenous therapy is needed. Mefloquine, which is currently recommended for prophylaxis against chloroquine-resistant P. falciparum, is also effective for single-dose oral treatment, although this regimen has not yet been approved by the Food and Drug Administration. Metronidazole has been widely used for treatment of gastroenteritis due to Entamoeba histolytica and Giardia lamblia (not approved by the Food and Drug Administration for the latter) and is considered safe and effective. A new macrolide, azithromycin, has been reported to be effective for cryptosporidiosis in experimental animals; currently, no effective therapy is available for human infections. Combinations of sulfonamides with other antifolates, trimethoprim or pyrimethamine, are recommended therapy for Pneumocystis carinii pneumonia or toxoplasmosis, respectively. Therapies for the various types of leishmaniasis and trypanosomiasis are complex, often toxic, and often of limited efficacy. The benzimidazoles are effective for roundworm infections, although thiabendazole has severe toxic effects. The recent introduction of ivermectin has revolutionized the treatment and control of onchocerciasis. Another relatively new agent, praziquantel, is a true broad-spectrum anthelmintic agent that is effective against most trematodes, many adult cestodes, and larval cestodes as well (especially cysticerci of Taenia solium).
 ...
PMID:Antiparasitic agents. 154 96

Molecular cloning technology has been gradually used in the studies of parasitic diseases in China since 1986. The information briefly reviewed here deals mainly with: (1) the molecular cloning of immunogen genes related to Schistosome and Plasmodium; (2) a diagnostic DNA probe for malaria and toxoplasmosis; and (3) DNA probes for inter- and intra-specific differentiation of Leishmania, Schistosome, Entamoeba, etc.
 ...
PMID:An overview of molecular parasitology in China. 159 82

Infections with parasitic protozoa have always been problems for the developing world and are becoming of greater importance to the developed world in this age of easy international travel. The major human protozoal diseases are summarised with an emphasis on their presentation in normal hosts and in immunocompromised individuals and current US drug treatment recommendations are discussed. Present antiprotozoal regimens are based either on a pharmacokinetic rationale or on clinical trial and error. Regimens based on trial and error include amphotericin B against leishmaniasis and arsenic against African trypanosomiasis. Regimens which are to some extent driven by pharmacokinetic or biochemical considerations include paromomycin and metronidazole against amoebiasis, sodium stibogluconate against leishmaniasis, halofantrine and mefloquine against malaria, dihydrofolate reductase (DHFR) inhibitors against Pneumocystis carinii and toxoplasmosis and aerosolised pentamidine against P. carinii pneumonia. The majority of pharmacokinetic studies have been performed only on agents which have some therapeutic activity against other diseases of the developed world. Despite the trend toward rational treatment regimens, no studies have been performed that permit optimisation of antiprotozoal treatment regimens on the basis of clinical conditions such as renal failure.
 ...
PMID:Pharmacokinetic justification of antiprotozoal therapy. A US perspective. 178 41

In this study the clastogenic effect of pyrimethamine (Daraprim), a folic acid antagonist used for the treatment of toxoplasmosis and malaria on human chromosomes, was investigated. Pyrimethamine was added to in vitro lymphocyte cultures at six different concentrations: 0.05 (normal therapeutic dose), 0.1, 0.2, 0.4, 0.8, and 1.6 mg/ml. No proliferation was observed in any of the cultures containing 1.6 mg/ml pyrimethamine. The results of the cytogenetic evaluations show that the frequency of breaks and gaps increase significantly in dose-dependent manner. Thus, pyrimethamine has a clastogenic effect on human chromosomes.
 ...
PMID:The clastogenic effect of pyrimethamine (Daraprim) on human chromosomes in lymphocyte cultures. 179 9


1 2 3 4 5 6 7 8 9 10 Next >>